Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure . It is a synthetic prostaglandin F2alpha analog . Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension . Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride . Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma .
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension .
Travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma .
The Eye Associates of Manatee, Manatee, Florida, United States
North Bath Eye Associates, Inc., Petaluma, California, United States
Center for Sight, Sarasota, Florida, United States
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States
Songklanagarind Hospital, Hatyai, Songkhla, Thailand
University of Montreal, Montreal, Quebec, Canada
University Eye Clinic, Parma, Italy
S.V. Malayan Ophthalmological Center, Yerevan, Armenia
S.V. Malayan Ophthalmological Center, Yerevan, Armenia
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Arlington Eye Physicians, Arlington Heights, Illinois, United States
Summa Health System, Akron, Ohio, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.